Behçet's disease
Behçet's disease is a systemic variable-vessel vasculitis with a classic triad of recurrent oral aphthous ulcers, genital ulcers, and uveitis — frequently accompanied by skin lesions (erythema nodosum, papulopustular eruption), arthritis, gastrointestinal involvement (terminal ileum ulceration that can mimic Crohn's), neurological involvement (neuro-Behçet's), and vascular involvement (deep vein thrombosis, pulmonary artery aneurysms, arterial vasculitis). Prevalence is highest along the historic Silk Road — Turkey, Iran, Israel, Japan, Korea — with strong HLA-B51 association. Disease typically presents in the 20s to 40s. Diagnosis follows ISGBD 1990 or ICBD 2014 criteria. Management is rheumatology-anchored per EULAR 2018: colchicine first-line, apremilast (Otezla, FDA 2019 via RELIEF Phase 3) for oral ulcers, adalimumab (FDA via VISUAL trials) for non-infectious uveitis, infliximab for severe uveitis + neuro-Behçet's + GI Behçet's, interferon-alpha for refractory ocular disease, azathioprine + cyclosporine + cyclophosphamide for severe disease. American Behçet's Disease Association is the principal patient organization. No peptide in the Juno library has a defensible Behçet's discovery-card case. Twenty-fifth deliberate non-elevation.
What changes during this transition
Behçet's disease arrives at the peptide-companion library through a specific community thread — patients carry recurrent oral aphthous ulcers, genital ulcers, and frequently GI tract ulcers, and the peptide community has a long-running framing that anything labeled 'healing peptide' should be considered for any ulcer condition. That framing is wrong in Behçet's, and the editorial response across all five substrate entries is to say so honestly rather than to manufacture a discovery card. The load-bearing reason no peptide elevates to discovery here is mechanistic, not just empirical. Behçet's is a systemic variable-vessel vasculitis with strong HLA-B51 immunogenetic anchoring, Th1/Th17 polarization, neutrophilic hyperactivity, and neutrophil extracellular trap (NET) involvement. The disease is not a mucosal-healing-deficit syndrome that happens to manifest in the mouth and genitalia — it is an immune-driven systemic vasculopathy whose ulcers are downstream manifestations of vessel-wall and mucosal vasculitis. Interventions that promote angiogenesis (BPC-157's preclinical profile) are mechanistically pointed in the wrong direction when the vessel wall is the antigen target. Interventions that activate T-cell responses (Thymosin alpha-1's registered hepatitis-B mechanism) are pointed in the wrong direction when the therapeutic goal is dampening Th1/Th17 hyperactivity. Interventions that amplify neutrophilic inflammation or drive type I interferon responses through TLR9 (LL-37's documented role as an autoantigen in cutaneous lupus and psoriasis) are pointed in the wrong direction when the disease is HLA-B51-anchored and neutrophil-driven. KPV has the most coherent mechanistic story (α-MSH-derivative mucosal anti-inflammatory with small inflammatory-bowel-disease pilot data), but Rule 6 prohibits propagating IBD pilot data to Behçet's without Behçet's-specific evidence, which does not exist. NMN is in the conversation only because general-aging supplements get pulled into every chronic condition by community generalization. The multi-jurisdictional posture is load-bearing here for a different reason than for Semax or Selank. Behçet's clinical research is concentrated in the source jurisdictions where the disease is most prevalent — Turkish, Iranian, Israeli, Japanese, and Korean rheumatology and ophthalmology groups have driven much of the trial evidence for interferon-alpha in refractory uveitis, for the adalimumab and infliximab experience in Behçet's-specific cohorts, and for the colchicine and apremilast Phase 3 data that anchor first-line therapy. The American Behçet's Disease Association is the principal US patient organization, and EULAR 2018 represents the European consolidated guideline, but the discovery and characterization of Behçet's as a distinct disease entity is Hulusi Behçet's 1937 Turkish dermatology work, and the modern evidence base reflects the Silk Road epidemiology honestly. The point for this substrate: 'the evidence does not exist for these peptides in Behçet's' is not a source-jurisdiction-blindness statement — Turkish, Iranian, Israeli, Japanese, and Korean rheumatology has been publishing Behçet's trial data for decades, and none of those groups have characterized BPC-157, KPV, Thymosin alpha-1, LL-37, or NMN in Behçet's. The absence here is across the entire international rheumatology literature. The disease itself is serious. Behçet's uveitis is sight-threatening — untreated or inadequately treated panuveitis with retinal vasculitis is a leading cause of preventable blindness in young adults along Silk Road geographies. Pulmonary artery aneurysms in vascular Behçet's are life-threatening, with a complex anticoagulation calculus because the aneurysms can bleed catastrophically. Neuro-Behçet's can mimic multiple sclerosis on imaging and has its own treatment trajectory. GI Behçet's terminal ileum ulceration can perforate. The right relationship with the disease is rheumatologist-anchored, multidisciplinary (ophthalmology, dermatology, neurology, gastroenterology, vascular surgery), and follows established guidelines — EULAR 2018 in Europe, the ISGBD/ICBD criteria internationally. Peptide adjuncts of unproven Behçet's-specific value, particularly those with mechanism-direction concerns in autoimmune vasculitis, are not where clinical attention belongs.
Important caveat
Behçet's disease is a rheumatology-managed systemic vasculitis; care belongs with a rheumatologist (and the appropriate subspecialists — ophthalmologist for any uveitis, dermatologist for mucocutaneous flares, neurologist for any cognitive or focal neurological symptom that might represent neuro-Behçet's, gastroenterologist for any GI symptom that might represent terminal ileum ulceration, vascular surgeon and pulmonologist for any vascular Behçet's component including DVT or pulmonary artery aneurysm, dental and oral medicine for refractory aphthae). Diagnosis follows ISGBD 1990 or ICBD 2014 criteria — both should be applied by a clinician familiar with the disease, particularly outside high-prevalence jurisdictions where diagnostic delays are common. Standard-of-care therapy follows EULAR 2018: colchicine first-line for mucocutaneous and arthritic disease, apremilast (Otezla) for oral ulcers with FDA approval via RELIEF Phase 3 (NEJM 2019), adalimumab for non-infectious uveitis including Behçet's uveitis with FDA approval via VISUAL trials, infliximab for severe uveitis + neuro-Behçet's + GI Behçet's, interferon-alpha for refractory ocular disease (substantial Turkish, Iranian, and German experience), azathioprine and cyclosporine as older standards for sight-threatening uveitis, cyclophosphamide for severe vascular Behçet's or neuro-Behçet's, tocilizumab in refractory cases per emerging case-series evidence. Anticoagulation in vascular Behçet's is controversial because of bleeding risk from pulmonary artery aneurysms — that decision is vascular-surgery and rheumatology-coordinated, not patient-led. Sight-threatening uveitis is a medical urgency; new or worsening eye symptoms (pain, redness, photophobia, blurred vision, floaters) require same-day ophthalmologic assessment. Suspected neuro-Behçet's (headache pattern change, focal neurological deficit, brainstem symptoms, cognitive change) requires urgent neurology workup with MRI. Suspected pulmonary artery aneurysm (hemoptysis, chest pain, dyspnea) is a medical emergency. Suspected GI Behçet's perforation (acute abdominal pain) is a surgical emergency. None of the peptides discussed (BPC-157, KPV, Thymosin alpha-1, LL-37, NMN) have controlled trial evidence in Behçet's; several have mechanism-direction concerns specific to autoimmune vasculitis (TA-1's T-cell-activation direction, LL-37's documented autoantigen role in cutaneous lupus and psoriasis with shared neutrophilic and IFN biology, BPC-157's angiogenic profile in a vessel-wall-antigen disease). Any peptide consideration must be disclosed to the rheumatologist BEFORE starting — interaction profiles with colchicine, apremilast, adalimumab, infliximab, interferon-alpha, azathioprine, cyclosporine, tocilizumab, and cyclophosphamide are uncharacterized for all five peptides. Sourcing channels are research-chemical or compounding-pharmacy with no quality assurance; TA-1 is a registered pharmaceutical (Zadaxin) in registered jurisdictions only — outside those jurisdictions, sourcing is unregulated. American Behçet's Disease Association is the principal US patient organization and a legitimate first-stop resource. WADA athletes: BPC-157 (S0) and TB-500 (S2) prohibited at all times — neither has a Behçet's use case anyway. Pregnancy: Behçet's pregnancies are typically rheumatology + maternal-fetal medicine + ophthalmology coordinated; colchicine generally continued; apremilast pregnancy data limited; adalimumab and infliximab with pregnancy-specific guidance (certolizumab preferred in third trimester for low placental transfer); cyclophosphamide and methotrexate ABSOLUTELY CONTRAINDICATED. This substrate is editorial honesty for /ask probing; it is not a recommendation to use any of these peptides in Behçet's disease.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.